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Abstract: Cytokine and growth factor signaling mediates essential roles in the differentiation, proliferation, survival 
and function of a number of cell lineages. This is achieved via specific receptors located on the surface of target 
cells, with ligand binding activating key intracellular signal transduction cascades to mediate the requisite cellular 
outcome. Effective resolution of receptor signaling is also essential, with excessive signaling having the potential for 
pathological consequences. The Suppressor of cytokine signaling (SOCS) family of proteins represent one important 
mechanism to extinguish cytokine and growth factor receptor signaling. There are 8 SOCS proteins in mammals; 
SOCS1-7 and the alternatively named Cytokine-inducible SH2-containing protein (CISH). SOCS1-3 and CISH are 
predominantly associated with the regulation of cytokine receptor signaling, while SOCS4-7 are more commonly 
involved in the control of Receptor tyrosine kinase (RTK) signaling. Individual SOCS proteins are typically induced 
by specific cytokines and growth factors, thereby generating a negative feedback loop. As a consequence of their 
regulatory properties, SOCS proteins have important functions in development and homeostasis, with increasing 
recognition of their role in disease, particularly their tumor suppressor and anti-inflammatory functions. This review 
provides a synthesis of our current understanding of the SOCS family, with an emphasis on their immune and he-
matopoietic roles.
Keywords: SOCS, development, immunity, disease, JAK-STAT, cytokine, growth factor, signalling, receptor tyrosine 
kinase
Introduction
Overview
Cytokines and growth factors are important 
mediators of cell-cell communication. These 
glycoproteins are secreted by cells in response 
to normal developmental cues or environmen-
tal stimuli to relay information to specific target 
cells expressing the appropriate receptor on 
their surface. Receptor binding initiates a range 
of intracellular signaling cascades that lead to 
appropriate cellular responses, such as prolif-
eration, differentiation, survival and functional 
activation [1, 2]. Subsequent dissipation of 
receptor signaling is essential to ensure the 
response of the cell does not become patho-
genic. The Suppressor of cytokine signaling 
(SOCS) proteins represent one key mechanism 
by which this level of control is achieved [3, 4].
SOCS structure and function
There are eight mammalian SOCS family mem-
bers; SOCS1-7 and the alternatively named 
Cytokine-inducible SH2-containing protein 
(CISH) [5] (Figure 1). While SOCS proteins are 
able to regulate signaling downstream of a 
range of receptors, current evidence indicates 
that CISH and SOCS1-3 are most often associ-
ated with regulation of cytokine receptor signal-
ing through the JAK-STAT pathway, while SOCS4-
7 predominantly regulate growth factor receptor 
signaling [6-8]. This difference reflects their 
evolutionary history, with the precursors to the 
SOCS4-7 sub-family existing prior to the emer-
gence of a functional cytokine receptor path-
way, while the sub-family comprising of SOCS1-
3 and CISH emerged later, co-incident with the 
cytokine receptor family [9, 10]. Within each 
sub-family, pairs of SOCS proteins have similar 
structure and function: CISH/SOCS2, SOCS1/
SOCS3, SOCS4/SOCS5 and SOCS6/SOCS7, 
again reflecting their evolutionary history [9].
Each SOCS protein contains three distinct 
domains; an N-terminal domain of low conser-
vation, a conserved central Src-homology 2 
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(SH2) domain, and a more highly conserved 
C-terminal domain termed the SOCS box. The 
N-terminal domain is variable in length between 
members, with SOCS1-3 and CISH having a 
shorter N-terminal domain in comparison to 
SOCS4-7 [11]. Within the N-terminal domains 
of SOCS1 and SOCS3 is a so-called kinase-
inhibitory region (KIR), which is responsible for 
inhibition of cytokine receptor-associated 
Janus kinases (JAKs) [12]. SOCS4 and SOCS5 
also possess a highly conserved region within 
their N-terminal domain, termed the N-terminal 
conserved region (NTCR), although the role of 
this sequence has not been elucidated [13]. In 
contrast, the N-terminal domains of SOCS6 and 
SOCS7 have been shown to be required for 
their respective nuclear translocation and, in 
the case of SOCS7, appears to be involved in 
transporting other proteins into the nucleus 
[14-16]. The SH2 domains of the SOCS proteins 
interact in a context-specific manner with phos-
photyrosine residues present on their target 
proteins, including cell surface receptors, 
imparting on SOCS proteins their target speci-
ficity [4]. These are longer than typical SH2 
domains due to a so-called extended SH2 
sequence (ESS) also found in STAT1 and STAT3, 
which contributes to their function [12]. Finally, 
the SOCS box is comprised of two functional 
sub-domains; a BC box that recruits Elongin B 
and C, and a Cul box that mediates Cullin5 
binding. The resulting complex is able to bind 
RBX2, leading in turn to recruitment of the 
remaining components of an E3 ubiquitin ligase 
complex [17, 18].
Figure 1. Structural and functional relationships amongst SOCS proteins. SOCS proteins can be grouped into pairs 
with similar structure and function, and these further grouped into those mainly acting on Cytokine receptor (CytoR) 
signaling and those mainly acting on Receptor tyrosine kinase (RTK) signaling, reflecting evolutionary relationships. 
All SOCS proteins consist of three conserved domains, the N-terminal, SH2 and SOCS box domains. The N-terminal 
domain is the least conserved and has a variety of roles, with specific sub-domains identified in certain SOCS pairs, 
including the kinase inhibitory region (KIR) in SOCS1 and SOCS3 and the N-terminal conserved region (NTCR) in 
SOCS4 and SOCS5. The SH2 domain is lengthened by the addition of an extended SH2 sequence (ESS) and is in-
volved in substrate binding via interaction with specific phosphotyrosine residues on the target protein. The SOCS 
box consists of BC box and Cul box sub-domains that recruit Elongin B and C, Cullin5, RBX1 and other E3 ligase 
components to mediate ubiquitination of target proteins and their subsequent proteasomal degradation.
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Control of signalling by SOCS proteins
Certain members of the SOCS family, typically 
SOCS1-3 and CISH, are induced by cytokine 
receptors and serve to extinguish signaling 
from the same receptor, providing a classical 
negative feedback loop [19] (Figure 2A). This 
occurs via activation of receptor-associated 
Janus kinases (JAKs), which phosphorylate 
tyrosine residues on the receptor complex to 
recruit signaling molecules, including Signal 
Transducer and Activator of Transcription (STAT) 
proteins. These also become tyrosine phos-
phorylated, leading to dimerization and nuclear 
translocation, where they stimulate transcrip-
tion of target genes. They include SOCS genes, 
the encoded proteins of which are able to inhib-
it intracellular signaling by a number of differ-
ent mechanisms that vary between individual 
family members. All SOCS proteins are able to 
regulate receptor signaling through the recruit-
ment of proteasomal degradation components 
to their target proteins, be they specific recep-
tors or associated molecules. This is achieved 
by binding to these targets through their SH2 
domains and recruitment of Elongin B/C het-
erodimers, Cullin5 and other components of a 
E3 ubiquitination complex via their SOCS box 
[18, 20]. SOCS-associated molecules are then 
readily able to be ubiquitinated, which typically 
targets these proteins to the proteasome. 
SOCS members can also regulate signaling via 
alternate methods. This is particularly true of 
SOCS1 and SOCS3, which bind Cullin5 at a 
much lower affinity than other SOCS proteins 
and remain partially active even in the absence 
of their SOCS box [20, 21]. As an alternative 
mechanism, SOCS1 and SOCS3 are able to 
directly inhibit JAK kinases, binding via their 
KIR domain to the JAK activation loop to inhibit 
kinase activity [12, 22-24]. CISH, SOCS2 and 
SOCS3 can also inhibit signaling via their ability 
to bind to phosphotyrosine residues typically 
on receptors, thereby blocking access of other 
SH2-containing signaling molecules [11, 
25-28].
Figure 2. Signaling via by cytokines and growth factors and its negative regulation by SOCS proteins. Cytokines (A) or 
growth factors (B) bind to their respective cell surface receptors, Cytokine receptors (CytoRs) and Receptor tyrosine 
kinases (RTKs), leading to receptor dimerization. For CytoRs this leads to activation of associated intracellular JAKs, 
which phosphorylate tyrosine residues on the receptor complex, creating docking site for STATs. These are then 
phosphorylated, enabling dimerization with other STATs, followed by translocation to the nucleus, where they act as 
transcription factors to induce expression of target genes that mediate a range of biological processes. These tar-
gets include SOCS genes capable of regulating receptor signaling, creating a negative feedback loop. RTKs possess 
intrinsic tyrosine kinase activity and may by-pass JAK and/or STAT activation. Individual SOCS proteins negatively 
regulate signaling by several mechanisms: degradation of receptors or associated proteins via the proteasomal 
pathway; inhibition of JAK tyrosine activity; competition for receptor phosphotyrosine residues thereby blocking 
other signaling molecules; prevention of nuclear translocation of key signaling molecules. 
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Table 1. Function of SOCS proteins revealed by mouse models
Knockout Transgenic
SOCS protein Type Phenotype Affected pathway REF Phenotype Affected pathway REF
CISH Not yet reported [256] Growth retardation GH/STAT5B [54]
Lactation failure PRL/STAT5A [54]
Reduced γδ T and NK cells IL-2/STAT5 [54]
Altered T cell response IL-2/STAT5 [54]
SOCS1 Complete Neonatal death IFNγ [90, 91] Spontaneous T cell activation γc cytokines [257]
Complete Lymphopenia IFNγ [91] Defective T cell development γc cytokines [257]
Complete Monocytic organ infiltration IFNγ [90] Fewer γδ T cells γc cytokines [257]
Complete Fatty degeneration /liver necrosis IFNγ/STAT1 & IL-4/STAT6 [90]
Complete+IFNγ-/- Polycystic kidneys ? [93]
Complete+IFNγ-/- Chronic inflammatory lesions ? [93]
Complete+IFNγ-/- Perturbed T cell development γc cytokines [94, 95]
Complete+IFNγ-/- Sensitive to LPS TLR [69]
T cell Increased CD8+ differentiation γc cytokines [98]
Complete but T&B cells Splenomegaly IL-4/IFNγ [52]
Complete but T&B cells Lymphadenopathy IL-4/IFNγ [52]
Complete but T&B cells Spontaneous dermatitis IL-4/IFNγ [52]
SOCS2 Complete Gigantism GH/STAT5B/IGF-1 [140] Gigantism GH/STAT5B/IGF-1 [143]
SOCS3 Complete Embryonic lethal LIF [190, 258] Embryonic lethal/anaemia EPO/STAT5 [258]
Complete+LIF+/- Death by 190 days ? [192]
Hematopoietic Neutrophilia/Inflammatory conditions G-CSF [181]
Neuronal Resistance to diet induced obesity Leptin [259]
Complete but T cells Perturbed CD8+ T cell proliferation  IL-6 & IL-27 [180]
SOCS4 Not yet reported  Not yet reported
SOCS5 Complete No reported phenotype [233] Reduced Th2 differentiation IL-4 [28]
SOCS6 Complete Mild growth retardation IGF-1 [7] Increased glucose metabolism INS/p85 [241]
SOCS7 Complete (mixed b/g) Altered glucose homeostasis INS [8, 252] Not yet reported
Complete (mixed b/g) Large pancreatic islets ?INS [8]
Complete (C57BL b/g) Hydrocephalus/growth retardation ?INS & IGF-1 [252]
Complete (mixed b/g) Cutaneous disease [254]  
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In the case of growth factors, intracellular sig-
nalling is mediated by so-called receptor tyro-
sine kinases (RTKs), with SOCS4-7 more typi-
cally involved in their regulation, although the 
factors regulating their expression are less well 
characterized (Figure 2B). The SOCS proteins 
regulate RTKs via target protein degradation, 
and in the case of SOCS4 and SOCS5 also bind-
ing site competition, while SOCS7 has been 
shown to directly bind signaling proteins to pre-
vent their nuclear translocation, thereby inhibit-
ing their ability to signal [29]. However, the divi-
sion of SOCS proteins between cytokine 
receptor and RTKs is not strict. Moreover, SOCS 
proteins can also participate in cross-talk 
between receptors and also regulate other 
pathways, such as Toll-like receptors (TLRs).
Role of SOCS proteins
The function of individual SOCS proteins has 
been investigated by a range of approaches, 
with mouse knockout (KO) and transgenic (Tg) 
models revealing important roles in develop-
ment (Table 1). Moreover, the SOCS proteins 
are being increasingly implicated in disease 
(Table 2).
CISH
CISH, the founding member of the SOCS family, 
was identified as an immediate-early gene 
induced in hematopoietic cells in response to 
stimulation by a variety of cytokines, including 
erythropoietin (EPO), interleukin-2 (IL-2), IL-3, 
and granulocyte-macrophage colony-stimulat-
ing factor (GM-CSF), which encoded a protein 
that was able to bind to activated cytokine 
receptors [30, 31]. Subsequent studies 
revealed induction by growth hormone (GH), 
prolactin (PRL) [32-34], IL-9 [35], thrombopoi-
etin (TPO) [36, 37] and granulocyte colony-
stimulating factor (G-CSF) [38], each of which 
also activate STAT5. In mice, strong expression 
of Cish was observed in the kidney, lung and 
liver [30], with lower expression in heart, stom-
ach, testis, spleen, and thymus [30, 36]. 
Stat5a/b KO mice had no detectable Cish 
expression [39, 40], underpinning the key role 
of STAT5 in CISH gene regulation. Indeed, CISH 
has been shown to be a direct STAT5 target 
gene, with two sets of conserved tandem STAT5 
binding sites present in its promoter [31, 41]. 
CISH is also induced by IL-6 [36], IL-10 [42], 
interferon (IFN)α [43], IFNγ [36], tumor necrosis 
factor (TNF)α [36], thymic stromal lymphopoi-
etin (TSPL) [44], leptin [45], and ciliary neuro-
tropic factor (CNTF) [46]. Finally, CISH has been 
found to be an early response gene induced by 
T cell receptor (TCR) stimulation via an alterna-
tive pathway not involving STAT5 [47]. Recent 
studies suggest that CISH is regulated post-
transcriptionally by microRNAs (miRs), with 
miR-98 or let-7 shown to target the 3’ untrans-
lated region (UTR) of the CISH mRNA, causing 
translational repression. Stimulation with bac-
terial lipopolysaccharide (LPS) or 
Cryptosporidium parvum infection in vitro was 
able to decrease expression of miR-98 and let-
7, thereby relieving the miR-mediated transla-
tional suppression of CISH [48]. The CISH 
3’UTR also contains ATAA destabilisation 
motifs, while the CISH protein possesses PEST 
sequences, which lead to rapid turnover of the 
mRNA and protein, respectively [30].
CISH is known to negatively regulate signaling 
induced by EPO [31], GH [26], IL-2 [49], IL-3 
[30], and PRL [34, 50]. CISH binds via its SH2 
domain to phosphorylated tyrosine residues of 
activated cytokine receptors, where it sup-
presses signaling via at least two mechanisms 
[25, 26]. Firstly, CISH can bind to the same 
receptor phosphotyrosine sites as STAT5, 
thereby physically blocking further STAT5 dock-
ing, which has been demonstrated for the EPO 
receptor (EPOR) and growth hormone receptor 
(GHR) [25, 26, 51]. CISH can also negatively 
regulate signaling at the receptor level by facili-
tating proteasomal degradation of activated 
receptor complexes via interactions between 
its SOCS box, Elongin B/C and Cullin5 [52, 53]. 
Interestingly, CISH has been suggested to be a 
positive regulator of TCR-mediated MAPK acti-
vation in T cells, with increased levels of CISH 
promoting TCR-mediated T cell proliferation 
and cytokine secretion [47], although the 
mechanism remains to be elucidated.
Transgenic mice expressing CISH under the 
control of the β-actin promoter exhibited growth 
retardation caused by reduced GHR signaling, 
defective mammary gland development due to 
disrupted PRL receptor (PRLR) signaling, and 
altered T and Natural killer (NK) cell responses 
as a result of blunted IL-2R signaling in T cells 
[54]. These phenotypes were consistent with 
those observed in Stat5a/b-deficient mice [39, 
40], suggesting a specific in vivo role in the 
regulation of STAT5. An alternate transgenic 
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mouse expressing CISH in CD4+ T cells showed 
inhibited TCR signalling, but in a STAT5-
independent manner [47].
No Cish KO mouse has been described. 
However, a recent study has indicated a role for 
CISH during the GM-CSF-mediated ex vivo 
development of mouse bone-marrow-derived 
dendritic cells (BMDCs). CISH was found to be 
induced by GM-CSF treatment, and CISH knock-
down caused a decline in MHC class I, pro-
inflammatory cytokines, and co-stimulatory 
Table 2. Association of SOCS proteins with disease
SOCS protein Disease  association Mechanism Reference
CISH Infectious disease susceptibility SNP at position -29 (blunted induction 
by IL-2)
[56]
Osteoarthritis Decreased expression [60]
SOCS1 Acute myeloid leukemia Hypermethylation [116, 117]
Glioblastoma multiforme Hypermethylation [127]
Barrett’s adenocarcinoma Hypermethylation [125]
Chronic myeloid leukemia Hypermethylation [118]
Breast cancer Hypermethylation [128]
Ovarian cancer Hypermethylation [128]
Cervical carcinogenesis Hypermethylation [123]
Esophageal squamous cell carcinoma Hypermethylation [124]
Hepatocellular carcinoma Hypermethylation & gene loss [126]
Chronic myeloid leukemia Constitutive expression [121]
Hodgkin lymphoma SOCS1 mutation, enhanced [113]
Primary mediastinal B-cell lymphoma Hypermethylation [115]
Tuberculosis Increased expression [134]
SOCS2 Ovarian cancer Hypermethylation [128]
Acromegaly associated colonic polyps Increased expression [162]
Osteoarthritis Decreased expression [60]
Type 2 diabetes 5’ SNP [61]
SOCS3 Lung cancer Hypermethylation [214]
Barrett’s adenocarcinoma Hypermethylation [125]
Hepatocellular carcinoma Hypermethylation [211]
Malignant melanoma Hypermethylation [212]
Glioma Hypermethylation [219]
Prostate cancer hypermethylation [220]
Ulcerative colitis (areas of dysplasia) Deceased expression [216]
Breast cancer with lymph node metastasis Reduced expression [221]
Atopic asthma/dermatitis (Th2 disease) Increased SOCS3 expression (periph-
eral T-cells)
[197]
Breast cancer with lymph node metastasis Reduced expression [221]
SOCS4 Gastric cancer Hypermethylation [229]
SOCS5 Uveitis Increased expression [236]
Thyroid gland cancer Decreased expression [239]
SOCS6 Gastric cancer Hypermethylation & gene loss [249]
Colorectal cancer Gene loss [251]
Primary lung squamous cell carcinoma Decreased expression [248]
Liver cancer Decreased expression [239]
Thyroid gland cancer Decreased expression [239]
SOCS7 Breast cancer Decreased expression [228]
Metabolic syndrome Specific haplotypes [255]
SOCS function
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molecule expression, concurrent with a sub-
stantial increase in the production of BMDCs 
via increased proliferation and reduced apopto-
sis. This was associated with enhanced STAT5 
activation. Therefore, CISH expression appears 
to regulate progenitor cell proliferation late in 
development via feedback inhibition of STAT5 
activation to allow differentiation to proceed 
effectively [55]. Functional analysis of a zebraf-
ish CISH homologue, cish.a, has revealed it to 
be a direct downstream target of the JAK2/
STAT5 pathway in vivo, with specific ablation of 
cish.a leading to a significant enhancement of 
embryonic erythropoiesis, myelopoiesis and 
lymphopoiesis, consistent with a role for CISH 
in the negative regulation of the JAK2/STAT5 
pathway in vivo (ACW, unpublished). 
CISH has also been implicated in disease. An 
association has been found between CISH sin-
gle nucleotide polymorphisms (SNPs) and sus-
ceptibility to infectious diseases, including bac-
teremia, malaria, and tuberculosis. A SNP at 
position -292 of the CISH promoter was the 
most highly associated, increasing the overall 
risk of infectious disease by at least 18% 
among persons carrying the variant allele. This 
allele blunted the induction of CISH mRNA fol-
lowing IL-2 stimulation, suggesting enhanced 
IL-2R signaling might be responsible for the 
increased susceptibility [56]. The -292 SNP 
was also found to be associated with hepatitis 
B virus infection in a Vietnamese population 
[57]. Other studies have suggested that CISH 
contributes to expansion of regulatory T cells 
(Tregs) in response to microbial infection [58]. 
Levels of CISH mRNA were also found to be 
higher in peripheral blood mononuclear cells 
(PBMCs) from systemic lupus erythematous 
(SLE) patients in acute phase compared to 
either normal individuals or patients with inac-
tive phase of disease, suggesting that CISH 
represents a marker of SLE and may be involved 
in disease pathogenesis [59]. Alterations in 
CISH levels have also recently been linked to 
osteoarthritis, although in this case CISH mRNA 
levels were found to be 10-fold lower in chon-
drocytes from osteoarthritic patients compared 
to control samples [60]. This suggests CISH 
plays a clinically-relevant role that might pro-
vide new strategies for controlling infectious 
agents and inflammatory diseases.
SOCS1 
SOCS1 was shown to be highly expressed in 
both mouse and human thymus and spleen [5, 
36, 61]. It was also expressed in the lung, testis 
[36], colon and mesenteric lymph nodes [5]. 
SOCS1 has been shown to be induced by 
numerous cytokines in vitro and ex vivo, includ-
ing IL-2 [62], IL-4 [22, 63], IL-6 [22], IL-13 [64], 
IFNα/β [65, 66], IFN-γ [36, 67], EPO [23, 36], 
G-CSF [22], LIF [22], PRL [34], GH [32], CNTF 
[46] and TNFα [68]. SOCS1 is also induced by 
Toll-like receptor (TLR) ligands, such as LPS 
[69, 70] and CpG DNA [71], as well as INS [72] 
and thyroid stimulating hormone (TSH) [73]. 
Bioinformatic analysis has identified the 3’UTR 
region of SOCS1 as a potential target of miR-
155. This miR is normally induced by TNF-α 
through the JNK pathway with knockdown of 
miR-155 in mouse osteoblastic cells resulting 
in increased SOCS1 protein expression follow-
ing TNFα stimulation. In contrast, transfection 
with miR-155 inhibited wild-type SOCS1 [74]. In 
T cells, FOXP3 negatively regulates miR-155 
thereby contributing to the maintenance of 
SOCS1 levels in these cells [75]. 
SOCS1 has also been found to regulate signal-
ing by a raft of receptors in vitro, including 
those for the cytokines IFNα [67], IFNγ [67], 
EPO [23], PRL [33, 34], GH [32, 51], LIF [22], 
TNF-α [68], IL-2 [23, 62], IL-3 [23], IL-4 [63], IL-6 
[22], IL-7 [76], IL-12 [77], IL-15 [78], EPO [23], 
TPO [36], TSLP [44], oncostatin M (OSM) [36], 
and leptin [79], as well as the receptors for INS 
[80] and IGF-1 [81], and the TLRs [82]. SOCS1 
is known to regulate signaling via two mecha-
nisms. Firstly, it can bind directly to cytokine 
receptor-associated JAK1, JAK2, and TYK2 to 
inhibit their tyrosine kinase activity via its ESS/
KIR domains, and consequently suppress acti-
vation of downstream pathways [12, 21-23]. 
However, like other SOCS family members, 
SOCS1 can also interact with Elongin B/C and 
Cullin5 via its SOCS box, facilitating ubiquitina-
tion and proteasomal degradation of target 
substrates [17, 83], including JAK1 [83], JAK2 
[84], TEL-JAK2 [85, 86], GEF, VAV [87], insulin 
receptor substrate (IRS)-1 and IRS-2 [88], as 
well the TLR2/4 adaptor protein MAL [82]. 
Interestingly, the SOCS box has also been 
shown to protect SOCS1 against proteolytic 
degradation [89].
SOCS1 has been shown to have several essen-
tial roles in immunity. Socs1 KO mice devel-
oped a fatal neonatal disease that resulted in 
death by three weeks of age [90, 91]. These 
animals exhibited severe lymphopenia and T 
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cell-mediated autoimmune inflammatory dis-
ease, characterized by monocytic infiltration of 
major organs along with fatty degeneration and 
necrosis of the liver [90]. These phenotypes 
were significantly reduced in Ifnγ/Socs1 double 
KO mice and in Socs1 KO mice treated with 
anti-IFNγ antibodies [92, 93], indicating that 
hyper-responsiveness to IFNγ was the chief 
cause and confirming SOCS1 as a potent in vivo 
regulator of IFNγ. However, these Ifnγ/Socs1 
double KO mice developed additional pheno-
types, including polycystic kidneys, chronic 
infections, and inflammatory lesions, which 
resulted in survival to only 6 months of age 
[93]. T cell development was also perturbed, 
including reduced T cells numbers [94], disrupt-
ed Th2 responses [95], a reduced CD4/CD8 
ratio [94], as well as abnormal development of 
Th17 cells [96], resulting from hypersensitivity 
to cytokines acting via the γc receptor: IL-2, 
IL-4, IL-7, IL-15 [97] and IL-12 [77]. 
T cell-specific Socs1 KO mice did not develop 
the lethal multi-organ inflammation, but rather 
specific lymphoid deficiencies, including 
increased differentiation toward CD8(+) T cells 
and phenotypes correlating with hypersensitiv-
ity to γc receptor utilizing cytokines [98]. These 
mice also showed a 10-fold increase in 
FOXP3(+) CD4(+) T regulatory (Treg) cells in the 
thymus, indicating SOCS1 potentially negative-
ly regulates the generation and/or accumula-
tion of these cells [99]. The increase in Treg 
cells was still apparent when these mice were 
crossed with those lacking IFNγ or IL-7 indicat-
ing other cytokines mediate this effect [99]. 
Further supporting a Treg role, mice lacking 
Socs1 expression in all but their T and B cells 
developed spontaneous dermatitis, spleno-
megaly, and lymphadenopathy. They showed 
an accumulation of DCs in their thymi and 
spleens, which were hyper-responsive to both 
IFNγ and IL-4, resulting in increased levels of 
BAFF/BLyS and APRIL, facilitating the genera-
tion of autoantibodies. This resulted in the 
development of systemic autoimmune-like dis-
eases with hypergammaglobulinemia at an 
early age [52]. Whilst it has been demonstrated 
that SOCS1 is important in helper T cell (Th) dif-
ferentiation, there is conflicting data regarding 
exactly which cell fate SOCS1 drives differentia-
tion towards. Some studies have suggested 
that SOCS1 favors Th1 differentiation, while 
others suggest that IL-6 induced SOCS1 blocks 
Th1 development via the inhibition of IFNγR, 
leading to accelerated Th2 differentiation 
[100]. To add to the complexity, SOCS1 has 
been shown to be necessary for Th17 differen-
tiation via its suppressive effects on IFNγ [101].
SOCS1 has been demonstrated to have several 
other in vivo regulatory functions. Thus, Socs1 
KO mice also showed impaired osteoblast dif-
ferentiation [102], as well as enhanced insulin 
signaling [103]. In addition, cells from SOCS1 
transgenic mice were unable to respond to LPS, 
suggesting that SOCS1 inhibited TLR/NF-κB 
signaling in vivo [69]. Socs1 deficiency also 
resulted in excessive macrophage and dendrit-
ic cell activation [52, 69], potentially caused by 
the combined effects of unrestrained signaling 
via IFNRAR1 [104] and TLRs [82, 105]. 
Knockdown of zebrafish socs1 resulted in per-
turbation of specific myeloid populations during 
embryogenesis prior to the commencement of 
lymphopoiesis, along with reduced numbers of 
T cells. Zebrafish SOCS1 was shown to interact 
with the zebrafish JAK2/STAT5 pathway both in 
vitro and in vivo. This demonstrated SOCS1 has 
a conserved role in T cell development, but 
exerts a T cell-independent function in embry-
onic myelopoiesis likely mediated via regulation 
of receptors that utilise the JAK2-STAT5 path-
way [106].
Defective SOCS1 signaling has been associat-
ed with a range of inflammatory disorders. In a 
murine arthritis model, SOCS1 was expressed 
in multiple cell types in the arthritic joint, with 
the extent of joint destruction and synovial 
inflammation exacerbated in Socs1 KO mice 
[107]. SOCS1 expression has been shown to 
correlate inversely with the severity of disease 
in idiopathic pulmonary fibrosis patients, with 
adenovirally-delivered SOCS1 decreasing fibro-
sis, inflammation and mortality in a murine 
model of pulmonary inflammation [108]. 
However, SOCS1 does not always confer pro-
tection against inflammatory/immune diseas-
es. Thus, SOCS1 Tg mice spontaneously devel-
op colitis, with severe intestinal inflammation 
[109]. Moreover, a SOCS1 promoter SNP that 
increases SOCS1 expression was associated 
with adult-onset asthma [110]. SOCS1 was also 
shown to protect β-cells from cytotoxic T cells in 
a murine type 1 diabetes model [111]. Further, 
increased expression of SOCS1 was observed 
in insulin-resistant mice, with down-modulation 
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of SOCS1 leading to increased insulin-sensitivi-
ty in these mice [112].
SOCS1 has also been suggested to have a 
tumor suppressor role, particularly in hemato-
logical malignancies and proliferative disor-
ders. Thus, the SOCS1 gene has been found to 
be frequently mutated in both classical Hodgkin 
lymphoma [113, 114] and primary mediastinal 
B-cell lymphoma [115], leading to augmented 
signaling by STAT5 [113, 115] and STAT6 [114]. 
The SOCS1 gene was commonly silenced by 
hypermethylation (and occasionally mutation) 
in acute myeloid leukemia [116, 117], with the 
reintroduction of SOCS1 causing growth sup-
pression in affected cells [117]. Chronic myeloid 
leukemia patients also demonstrated hyper-
methylation of SOCS1 that reverted to an 
unmethylated state during remission [118]. 
Some Philadelphia chromosome (Ph)-negative 
myeloproliferative disorders (MPDs) exhibit 
SOCS1 hypermethylation, which may comple-
ment other mutations, such as the hyperactive 
JAK2V617F mutation [119]. Others have alter-
natively found that SOCS1 is overexpressed in 
Ph-negative MPDs, potentially acting as a com-
pensatory feedback mechanism [120]. Indeed, 
constitutive expression of SOCS1 has been 
observed in chronic myeloid leukemia (CML)
[121], in line with hypomethylation of this gene 
[122]. SOCS1 expression in CML also correlat-
ed with a poor response to interferon α, treat-
ment, likely due to a direct effect on receptor 
signaling [121]. Hypermethylation of SOCS1 
has been commonly reported in solid tumors, 
including 61% of cervical cancer samples [123], 
and 45% of esophageal squamous cell carci-
noma samples [124], as well as occasionally in 
Barrett’s adenocarcinoma [125], with com-
bined hypermethylation/gene loss observed in 
hepatocellular carcinoma [126]. 
Hypermethylation-mediated silencing has also 
been seen in glioblastoma multiforme, with 
concomitant enhancement of radio-resistance, 
indicative of a pro-apoptotic function [127]. 
Hypermethy-lation of the SOCS gene has also 
been observed in breast and ovarian cancer, 
where SOCS1 reintroduction was again able to 
suppress cell growth [128]. Spontaneous 
colorectal cancer was also seen in Socs1 KO 
mice in an IFNγ-dependent manner [129]. 
Finally, SOCS1 has also been shown to sup-
press oncogenic forms of VAV [87], c-MET 
[130], ABL and c-KIT [131], as well as TEL-JAK2 
and BCR-ABL fusions [131]. 
SOCS1 also has roles in the response to infec-
tious agents. For example, SOCS1 has been 
shown to protect against lethal inflammation 
induced by Chlamydia pneumoniae, although it 
hampered bacterial clearance due to its effects 
on IFNα/β-induced STAT1 [132]. SOCS1 also 
inhibited the antiviral response to influenza 
[133], and increased SOCS1 levels were asso-
ciated with enhanced disease severity in tuber-
culosis [134]. In fact, many infectious agents 
specifically target SOCS1 to augment the infec-
tion process. Thus, Toxoplasma gondii induces 
SOCS1 expression leading to inhibition of cyto-
kine signaling and suppression of immune 
responses [135]. Similarly, Mycobacterium 
bovis increases SOCS1 and SOCS3 to inhibit 
IFNγ-induced STAT1 [136]. Furthermore, bacte-
rial flagellin was shown to act via TLR5 to induce 
SOCS1 thereby suppressing TCR-mediated T 
cell activation [137]. In contrast, hepatitis C 
core protein down-regulates SOCS1, resulting 
in enhanced STAT5 signaling in B cells [138]. 
SOCS2
SOCS2 was shown to be highly expressed in 
the fetal kidney [139], as well as adult kidney, 
lung, testes, liver [36, 139, 140], pancreatic 
islets [141], peripheral blood mononuclear leu-
kocytes [142], and to a lesser extent in adult 
heart, muscle and brain [139, 140]. SOCS2 is 
most closely related to CISH, and like CISH is 
induced by cytokines that activate STAT5, 
including GH [32, 143], EPO [36, 144], PRL [34] 
IL-2 [145], IL-3, GM-CSF and G-CSF [36]. 
However, it is also induced by CNTF [46], IFNα 
[43], IFNγ [36, 142], leukemia inhibitory factor 
(LIF) [36], IL-1β [142], IL-4 [36], IL-6 [142],IL-15 
[146] and insulin (INS) [72].
SOCS2 acts to regulate signaling induced by 
the cytokines GH [26], PRL [147], LIF [145], 
IL-2, IL-3 [148] and IL-6 [21], but also by growth 
factors, such as epidermal growth factor (EGF) 
[149] and insulin-like growth factor (IGF)-1 
[139]. SOCS2 differs from other SOCS family 
members in two important and interesting 
ways. Firstly, SOCS2 appears to play a dualistic 
regulatory role, both inhibiting and potentiating 
signaling dependent on its concentration and 
cellular context [21, 34, 150]. In vitro studies 
have demonstrated that low levels of SOCS2 
led to a reduction in GH signaling, while higher 
levels actually increased GH signaling [150]. 
Secondly, SOCS2 has been shown to possess 
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the ability to antagonize other SOCS family 
members [50]. Thus, SOCS1 inhibition of GH 
signaling was reduced with increasing doses of 
co-transfected SOCS2 [150], while SOCS2 was 
shown to exert an antagonistic role in the 
SOCS1- and SOCS3-mediated negative regula-
tion of IL-2 and IL-3 signaling, respectively 
[148]. SOCS2 primarily exerts its effects by 
stimulating ubiquitination of target proteins, 
including receptors, such as GHR [151], and 
signaling proteins, such as SOCS3 [148]. 
Socs2 knockout mice were indistinguishable 
from their littermates until 3 weeks of age, at 
which point they began to demonstrate 
increased overall growth, being 40% heavier 
than wild-type (WT) littermates by adulthood 
[140]. The increase in weight was due to 
increased bone length and enlargement of 
internal organs [140]. Constitutive expression 
of SOCS2 produced a similar phenotype, with 
SOCS2 transgenic mice being significantly larg-
er than WT animals [152], consistent with the 
dualistic nature of SOCS2. A naturally-occurring 
mouse mutant, high growth (hg), which exhibit-
ed a 30-50% increase in postnatal growth, has 
been mapped to the Socs2 region, indicating 
that hg is most likely an allele of Socs2 – 
although whether it is hypomorphic or hyper-
morphic allele remains to be determined [153]. 
Socs2 KO mice exhibited prolonged STAT5B 
activation in response to GH, and crossing with 
Stat5b KO mice partially relieved the growth 
enhancement [143]. This suggests that SOCS2 
regulates the GH/IGF-1 axis through negative 
regulation of the downstream STAT5B [140, 
143]. SOCS2 also has a role in controlling pro-
lactin-induced mammary gland development, 
which appears to be the result of enhanced 
STAT5A activation [147]. SOCS2 also exerts a 
dualistic role in the regulation of EGF signaling, 
with increased intestinal growth in Socs2 KO 
mice due to enhanced responsiveness to EGF 
[154], and increased neural outgrowth of corti-
cal neurons derived from SOCS2 transgenic 
mice, apparently also due to enhanced EGF sig-
naling [155]. Transgenic mice overexpressing 
SOCS2 specifically in pancreatic β-cells using 
the rat insulin promoter displayed hyperglyce-
mia and glucose intolerance, but did not exhibit 
overt diabetes [156]. In contrast, the pancreat-
ic β-cells of Socs2 KO mice showed unaltered 
insulin and glucose tolerance when compared 
to WT mice [157]. 
SOCS2 also functions in immune cells, with 
roles in both DCs as well as CD4+ T cells. When 
SOCS2 was silenced in DCs, maturation was 
disrupted and a reduction in LPS stimulated 
MAPK activation was observed [158], suggest-
ing a requirement for SOCS2 in TLR-induced DC 
activation. However, others have argued that 
SOCS2 is a TLR-responsive gene with its 
delayed expression providing a mechanism for 
late-phase counter-regulation to limit inflam-
mation-driving DC activity [159]. SOCS2 silenc-
ing in CD4+ T cells resulted in increased prefer-
ence for helper T cell (Th)2 differentiation, 
which is consistent with elevated Th2 respons-
es observed in SOCS2 KO mice [160]. In human 
NK cells, SOCS2 was shown to be induced by 
IL-15 and targeted PYK2 for degradation, with 
SOCS2 knockdown resulting in defective NK 
cell effector functions [146]. 
Like its close homologue CISH, SOCS2 has 
been linked to osteoarthritis, with SOCS2 
mRNA levels also found to be 10-fold lower in 
osteoarthritic samples when compared to con-
trol samples, with increased expression seen 
following cytokine treatment [60]. A SNP in the 
5’ region of the SOCS2 gene was associated 
with type 2 diabetes (T2D) in a Japanese popu-
lation. Adenovirus-mediated expression of the 
SOCS2 gene in pancreatic islets significantly 
suppressed glucose stimulated insulin secre-
tion, suggesting a likely mechanism by which 
SOCS2 may influence susceptibility to T2D [61]. 
SOCS2 also appears to be a cellular target of 
the HIV-1 transactivator protein (Tat) in primary 
human monocytes, leading to increased SOCS2 
levels, which was shown to suppress IFNγ-
activated STAT1 phosphorylation, resulting in 
dysregulated cytokine production and immune 
evasion [161]. Finally, SOCS2 has been impli-
cated in oncogenesis, where it also shows a 
dualistic nature. Patients with active acromega-
ly and colonic polyps showed a significantly 
increased SOCS2 expression, which mediated 
a reduction in SOCS1, leading to elevated 
STAT5B levels, potentially resulting in upregula-
tion of GH-mediated proliferation of colonic epi-
thelial cells [162]. In contrast, SOCS2 expres-
sion was shown to have a favorable prognostic 
value in breast cancer [163], and hypermethyl-
ation of SOCS2 was detected in ovarian but not 
breast cancer [128].
SOCS3
SOCS3 has been shown to be expressed in a 
wide variety of murine and human tissues. In 
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cytokine-induced STAT3 and STAT1 activation. 
Induction of SOCS3 is most pronounced by 
cytokines that strongly activate STAT3, with its 
regulatory specificity determined by the pres-
ence of high-affinity SOCS3-binding sites on 
target receptors.
Socs3 mouse KO embryos exhibited fatal pla-
cental defects during embryonic development 
and although anatomically sound, they did not 
survive past 13 days of gestation. These 
embryos showed expanded numbers of giant 
trophoblast cells in the placenta, as well as 
abnormities in the spongiotrophoblast and lab-
yrinth placental layers [190]. LIFR deficit was 
able to rescue the Socs3 KO placental defect 
and embryonic lethality, establishing SOCS3 as 
an essential regulator of LIFR signaling during 
placental formation [191]. However, these dou-
ble KO mice died by 190 days of age due to 
neutrophilia accompanied by inflammatory-cell 
tissue infiltration [192]. Hematopoietic-specific 
Socs3 KO mice developed a variety of inflam-
matory conditions, including a prolonged and 
enhanced responses to G-CSF that facilitated 
neutrophilia and enhanced progenitor cell sur-
vival, suggesting SOCS3 is an important in vivo 
regulator of G-CSFR signaling [181]. 
Interestingly, differentiation of SOCS3-deficient 
progenitors was skewed toward a macrophage 
state in response to G-CSF and IL-6 stimula-
tion, suggesting that SOCS3 is also important 
in maintaining the specificity of biological 
responses mediated by cytokine signaling 
[193]. SOCS3 was also shown to be a positive 
regulator of TLR4 responses in macrophages 
via inhibition of IL-6R-mediated STAT3 activa-
tion [194] as well as endogenous TGFβ-
mediated/SMAD3 [195]. Socs3 deficiency in 
either hepatocytes or macrophages resulted in 
prolonged IL-6-induced activation of STAT1 and 
STAT3, but normal IFNγ and IL-10 signaling 
[167, 188, 194]. These observations strongly 
suggest that SOCS3 targets GP130 dependent 
signal transduction pathways in vivo. 
SOCS3 has been shown to be selectively 
expressed in Th2 cells [196] and required for 
Th2 development. Mice heterozygous for Socs3 
or expressing a dominant-negative SOCS3 
showed reduced Th2 development, while those 
expressing a SOCS3 transgene exhibited 
enhanced Th2 polarity [197]. T cell-specific 
Socs3 KO mice showed increased CD8(+) T cell 
mice, SOCS3 was found to be expressed in the 
spleen, thymus, and lung [36], while in humans, 
SOCS3 was expressed in the colon, spleen, 
bladder, peripheral blood leukocytes, trachea 
and placenta, with very high expression in the 
lung, adipose tissue, ovary and aorta [61]. 
SOCS3 has been demonstrated to be induced 
by the cytokines IL-1β [164], IL-2 [165], IL-3 
[166], IL-4 [63], IL-6 [167], IL-9 [35], IL-10 [42], 
IL-11 [168], IL-13 [36], IL-22 [169], IFN-γ [67], 
IFNα [67], EPO [170], LIF [32], PRL [34], GH 
[32], leptin [171], G-CSF [36], GM-CSF [172], 
CNTF [46], TPO [66], TNFα [173], cardiotrophin 
(CT)1 [174], OSM [175]. It is also induced by 
several growth factors, including EGF [176, 
177], platelet-derived growth factor (PDGF) 
[176], thyroid stimulating hormone (TSH) [73], 
insulin [72], and basic fibroblast growth factor 
(BFGF) [178].
SOCS3 has been demonstrated to play a regu-
latory role in signaling downstream of a wide 
range of cytokine receptors, including those for 
IL-2 [165], IL-4 [63], IL-6 [21], IL-9 [35], IL-11 
[168], IL-23 [179], IL-27 [180], IFNα/β [67], IFNγ 
[67], G-CSF [181], EPO [170], PRL [33, 34], GH 
[32, 51], LIF [32], leptin [171], CNTF [46], IL-1β 
[182], OSM [175] and CT1 [174], as well as 
IGF-1 [81], INS [183], CD28 [184] and calcineu-
rin [185]. Like its closest homologue, SOCS1, 
the SOCS3 protein can directly inhibit receptor-
bound JAKs, although it achieves this via a 
high-affinity interaction between its SH2 
domain and a phosphotyrosine residue on the 
receptor (e.g. GP130), rather than the JAK 
[170], binding simultaneously to both [186]. 
SOCS3 also regulates signaling via binding site 
competition. Thus, SOCS3 has been shown to 
bind to the same site as the SH2-domain hema-
topoietic phosphatase (SHP)-2 on several 
receptors [27] and with STAT4 on others [187]. 
Finally, like other members of the SOCS family, 
SOCS3 can also regulate signaling by targeting 
proteins for degradation, however this is not its 
primary mechanism of action, as it can still reg-
ulate signaling without its SOCS box [21]. It has 
been demonstrated that an IL-6 transcriptional 
response can be converted to one mimicking 
that of interferons when SOCS3 is absent [167, 
188], while IL-7-induced viral clearance 
occurred via a mechanism that required both 
the induction of IL-6 and inhibition of SOCS3 
expression [189]. Collectively, this suggests 
that SOCS3 primarily functions by dampening 
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patients with Th2 type diseases, such as atopic 
asthma and dermatitis, where its expression 
has found to correlate tightly with disease 
severity [197]. Similarly, SOCS3 has been asso-
ciated with allergic conjunctivitis (AC), with high 
expression at the site of disease, with reduc-
tion of SOCS3 leading to decreased clinical 
severity [207]. 
SOCS3 appears to also play a tumor-suppres-
sor/anti-proliferative role. For example, over-
coming SOCS3 regulation seems to be a com-
mon theme in proliferative syndromes. Thus, 
the myeloproliferative disease-associated 
JAK2V617F mutant is no longer able to be nega-
tively-regulated by SOCS3 [208]. Similarly, 
G-CSFR truncations associated with severe 
congenital neutropenia leading to acute 
myeloid leukemia have lost the sequences 
required for SOCS3-mediated control of STAT5 
activation [209]. Once again though, the exact 
role for SOCS3 is complex. For example, overex-
pression of SOCS3 associated with decreased 
survival in a cohort of patients with de novo fol-
licular lymphoma [210], while SOCS3 may in 
fact potentiate the JAK2V617F mutation [208]. 
However, hypermethylation of SOCS3 occurs 
frequently in both Barrett’s adenocarcinoma 
[125] and hepatocellular carcinoma [211], in 
the latter case leading to increased JAK2/
STAT3 activation [211]. Hypermethylation medi-
ated reduction in SOCS3 expression has also 
been observed in malignant human melanoma 
[212], while constitutive SOCS3 expression 
was shown to confer a proliferative advantage 
to a human melanoma cell line [213]. SOCS3 
was also found to be frequently silenced by 
hypermethylation in human lung cancer where 
it suppressed cell growth [214]. SOCS3 was 
able to limit inflammation-associated tumori-
genesis in the colon, via regulation of STAT3 
and NFκB [215], while in ulcerative colitis, loss 
of SOCS3 expression was observed in the 
areas of colon dysplasia [216]. SOCS3 was pro-
tective against hepatitis-induced hepatocellu-
lar carcinoma, with loss of SOCS3 leading to 
resistance to apoptosis and increased prolifer-
ation [217]. Similar epigenetic silencing of 
SOCS3 has been seen in cholangiocarcinoma 
cells, resulting in enhanced IL-6/STAT3 signal-
ing and reduced apoptosis [218]. SOCS3 hyper-
methylation was also seen in glioma [219], and 
prostate cancer tissues – although not in 
benign prostate hyperplasia [220]. Finally, 
proliferation via enhanced IL-6 and IL-27 signal-
ing [180]. It has been suggested that the ability 
of SOCS3 to skew T cell differentiation to the 
Th2 phenotype may be due to an ability to com-
pete for the STAT4-binding site on the IL-12Rβ2 
chain, thus inhibiting IL-12/STAT4-driven polar-
ization to the alternative Th1 phenotype [187], 
or alternatively via its inhibition of interferon-
induced STAT1 activation that is also associat-
ed with Th1 polarization [167].
SOCS3 has diverse roles outside of the immune 
and hematopoietic lineages. Mammary stem/
progenitor cell-specific Socs3 KO mice exhibit-
ed impaired lactation resulting from reduced 
proliferation [198]. Loss of SOCS3 from differ-
entiated luminal cells resulted in accelerated 
tissue remodeling upon weaning [198]. SOCS3 
has also been shown to play a role in fine-tun-
ing photoreceptor cell differentiation [199], 
while SOCS3 transgenic mice showed reduced 
pancreatic β-cell mass and proliferation [200]. 
SOCS3 was also shown to be required for nor-
mal wound healing, again via action on GP130 
signaling [201]. Finally, elevated levels of 
SOCS3 in the arcuate nucleus of the hypothala-
mus have been associated with leptin resis-
tance and obesity in mice [171]. 
SOCS3 has also been associated with the pro-
gression of a number of inflammatory condi-
tions. SOCS3 expression has been reported in 
synovial tissue from mice during experimental 
arthritis, and in peripheral blood mononuclear 
cells in patients with rheumatoid arthritis (RA) 
[202]. Mice with a GP130 receptor mutation 
that ablates SOCS3 binding develop a RA-like 
joint disease [203]. Similarly, hematopoietic 
and endothelial cell-specific Socs3 KO mice 
exhibited severe phenotypes in experimental 
arthritis models, most likely due to enhanced 
responsiveness of IL-6, G-CSF and possibly IL-1 
[204]. Moreover, adenoviral delivered SOCS3 
could eliminate joint inflammation in mice with 
experimental autoimmune arthritis, mediate 
via inhibition of IL-6 signaling [205]. SOCS3 
was found to be highly expressed in lamina pro-
pria and epithelial cells in the colon of mice 
with inflammatory bowel disease (IBD), as well 
in human patients with both ulcerative colitis 
and Crohn’s disease (CD), again suggested to 
be due to enhanced IL-6 signaling (via STAT3) 
[206]. In contrast, SOCS3 has been found to be 
upregulated in the peripheral T cells from 
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a role for SOCS4 in the regulation of primordial 
follicle activation, a process initiated by LIF 
activation of the JAK1/STAT3 pathway. This 
occurred concurrently with SOCS4 induction, 
with SOCS4 shown to interact with several pro-
teins involved in ovarian follicular development 
[227]. No Socs4 KO mouse has been reported.
Several studies have suggested a tumor sup-
pressor role for SOCS4. An inverse relationship 
between SOCS4 expression levels and tumor 
node metastasis stage has been reported in 
human breast cancer [228]. SOCS4 expression 
was also found to be significantly lower in can-
cerous tissue compared to non-cancerous tis-
sue in a patient with gastric cancer, mediated 
by hypermethylation of CpG sites in the promot-
er region of the SOCS4 gene leading to SOCS4 
silencing [229]. Mouse studies also suggest a 
tumor suppressor in epithelial cells via RUNX1-
mediated repression of the SOCS4 promoter, 
leading to decreased SOCS4 levels and 
increased STAT3 activity, thereby contributing 
to tumor development [230].
SOCS5
SOCS5 is most closely related to SOCS4, and 
also has not been fully characterised. SOCS5 
has been shown to be expressed in a variety of 
adult tissues including heart, brain, retina, 
lung, colon, bladder, testis and skeletal muscle 
as well as the placenta [5, 225, 231, 232]. 
Expression was particularly high in lymphoid 
organs including the spleen, lymph nodes, thy-
mus, and bone marrow, with specific expres-
sion in primary B and T cells [233], suggesting 
possible immune-related functions [231]. Like 
SOCS4, SOCS5 expression has been shown to 
be induced by EGF in vitro [225].
SOCS5 appears able to regulate both RTK and 
cytokine receptor signaling. Thus, SOCS5 has 
been shown to negatively regulate EGFR in vitro 
[6, 225], and more weakly IL-6R, LIFR [21] and 
IL-4R signaling [28]. This seems to be a con-
served function since overexpression of the 
Drosophila melanogaster SOCS5 homologue, 
SOCS36E, resulted in several phenotypes con-
sistent with reduction in both cytokine receptor 
and EGFR signaling. SOCS5 is thought to regu-
late signaling by initiating the proteasomal deg-
radation of its target proteins, as seen in the 
regulation of EGFR, where both its SH2 domain 
and SOCS box required for initiation of degrada-
reduced expression of SOCS3 was also specifi-
cally observed in breast cancer with lymph 
node metastasis, suggesting a role in tumor 
spread [221]. 
SOCS3 has also been associated with infec-
tious diseases. For example, the severe inflam-
mation mediated by SARS virus infection was 
found to correlate with lower expression of 
SOCS3 in infected cells [222]. In contrast, 
SOCS3 was able to inhibit the antiviral response 
to influenza [133]. Indeed, pathogenic strains 
of Salmonella sp. could increase SOCS3 
expression in macrophages to mediate sup-
pression of immune responses [135]. Similarly, 
M. bovis was able to induce SOCS3 to mediate 
inhibition of IFNγ-induced STAT1 [136]. Finally, 
high levels of SOCS3 have been found to be 
associated with non-responsiveness to com-
bined IFN antiviral therapy [223].
SOCS4
SOCS4 remains the least studied member of 
the SOCS family. It has been shown to be par-
ticularly highly expressed in the intestine and 
thymus of adult pig [224], with the zebrafish 
socs4a homologue expressed in the embryonic 
nervous system (MCT and ACW, unpublished). 
Available mouse data suggests it is widely 
expressed, with higher expression in the olfac-
tory bulb (http://biogps.org/#goto=genereport
&id=122809). To date, SOCS4 has been shown 
to be induced only by EGF, at least in vitro [225]. 
Similar to CISH, miR-98 and let-7 are thought to 
post-transcriptionally regulate SOCS4, facilitat-
ing translational repression by targeting its 
3’UTR region. Infection of binary epithelial cells 
with C. parvum decreased miR-98 and let-7, 
leading to increased SOCS4 expression [226].
SOCS4 has been demonstrated to regulate 
EGFR signaling in vitro [6, 225]. This appears to 
be mediated through docking of SOCS4 to 
phosphotyrosine residues on the activated 
EGFR, subsequently targeting the receptor for 
proteasomal degradation by recruitment of E3 
ubiquitin ligase activity [6, 11]. However, SOCS4 
binds with high affinity to the same EGFR phos-
photyrosine as STAT3 and therefore may also 
inhibit STAT3 activation directly by blocking its 
ability to dock to EGFR [11]. SOCS4 also has a 
low micromolar affinity for JAK2 and c-KIT, the 
biological consequences of which remain to be 
determined [11]. A recent report has suggested 
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properties and impaired IL-4-induced STAT6 
activation [237]. Since STAT6 knockout mice 
have also been found to be resistant to septic 
peritonitis [238], this suggests a regulatory role 
for SOCS5 on the IL-4/STAT6 pathway. SOCS5 
transgenic mice also showed increased perito-
neal IL-2 and IFN-γ, cytokines involved in the 
promotion of Th1 differentiation [237]. Finally, 
a reduction in SOCS5 expression was observed 
in cancer of the thyroid gland [239], suggesting 
a possible tumor-suppressor function. 
SOCS6
SOCS6 has been shown to be ubiquitously 
expressed during mouse embryonic develop-
ment, while in the adult mouse expression has 
been reported in areas of the bone marrow 
containing monocytes and immature granulo-
cytes [7] and in the retina [232]. SOCS6 was 
found to be induced by both INS [240, 241] and 
IGF-2 [242].
SOCS6 has been demonstrated to negatively 
regulate signaling by IGF-1 [242], INS [240], 
FLT3 [243], Stem Cell Factor (SCF) [244] and 
TCR [245]. Like other SOCS proteins, SOCS6 
likely exerts its regulatory effects primarily 
through ubiquitination and degradation of tar-
get proteins [7]. However, SOCS6 interacts with 
an alternate E3 ligase component, heme-oxi-
dized IRP2 ubiquitin ligase-1 (HOIL-1), which 
induces the poly-ubiquitination and degrada-
tion of SOCS6-associated proteins [244]. Like 
SOCS2, SOCS6 also has the ability to degrade 
other SOCS proteins, including SOCS7 [246]. 
The SOCS6 N-terminal domain has been shown 
to drive localisation to the nucleus, where it 
appears to negatively regulate STAT3, although 
the exact mechanism by which SOCS6 regu-
lates STAT3 has not been identified [14].
SOCS6 has been shown to control TCR-
mediated T cell activation in vitro through nega-
tive regulation of p56lck. SOCS6 was shown to 
bind to the kinase domain of active p56lck, tar-
geting it for ubiquitination and subsequent deg-
radation, with SOCS6 overexpression resulting 
in repression of TCR-dependent IL-2 promoter 
activity [245]. SOCS6 also appears to negative-
ly regulate signaling of several important hema-
topoietic receptor tyrosine kinases. SOCS6 
binds to the juxtamembrane region of c-KIT fol-
lowing stimulation with SCF, thereby regulating 
activation of members of the MAPK pathway, 
tion [6, 225]. Interestingly, the SOCS5 protein 
has been found to associate with EGFR inde-
pendent of ligand stimulation, binding via its 
N-terminal domain [225].
Consistent with its expression in lymphoid 
organs and in vitro effects on IL-4 signaling, 
SOCS5 has been implicated in T helper cell dif-
ferentiation, particularly in the balance between 
Th1 and Th2 cells, with SOCS5 protein prefer-
entially expressed in Th1 cells. SOCS5 Tg mice 
showed a significant reduction in Th2 develop-
ment, thought to be facilitated by the ability of 
SOCS5 to inhibit IL-4R mediated STAT6 activa-
tion that normally stimulates differentiation of 
naïve T cells toward a Th2 fate [28]. Interestingly, 
SOCS5 was found to associate with the IL-4R 
regardless of tyrosine phosphorylation [28, 
225]. However, Socs5 KO mice showed no 
abnormalities in Th1/Th2 differentiation, indi-
cating possible redundancy in its lymphoid role 
[233].
SOCS5 has been implicated in a variety of dis-
ease states, such as allergic conjunctivitis 
[207], atopic dermatitis [234], asthma [235] 
and uveitis [236], although some of these asso-
ciations have so far only been identified in 
rodent models. These studies also provide fur-
ther support for a role for SOCS5 in regulating 
the balance between Th1 and Th2 cells. For 
example, SOCS5 expression was decreased in 
patients with the Th2 dominant disease atopic 
dermatitis (AD) compared to healthy controls, 
with patients demonstrating eosinophilia show-
ing even lower levels of SOCS5 [234]. Moreover, 
constitutive SOCS5 expression has been found 
to reduce eosinophil infiltration in allergic con-
junctivitis [207], further implicating SOCS5 in 
the balance of Th1/Th2 cells, since eosinophil 
production is stimulated by Th2 cytokines, 
including IL-4. This notion was further support-
ed in a murine model for allergic conjunctivitis, 
an ocular disease that is characterized by IL-4-
mediated eosinophil infiltration. In mice consti-
tutively expressing SOCS5 under the control of 
the lck proximal promoter and Eμ enhancer, 
decreased conjunctival eosinophil infiltration 
was observed [207]. These mice also showed 
decreased lethality to septic peritonitis and sig-
nificantly lower bacterial burden compared to 
WT controls. This was associated with accumu-
lation of neutrophils and macrophages, with 
these cells showing increased bactericidal 
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in the regulation of insulin receptor signaling, 
such as SOCS7 [7] or SOCS1 [80]. However, 
SOCS6 Tg mice utilizing the elongation factor I 
promoter displayed enhanced AKT activation in 
response to INS and increased glucose metab-
olism, supporting an in vivo role for SOCS6 in 
the regulation of INS signaling [241]. Finally, 
despite its expression in the bone marrow, no 
hematological phenotypes could be identified 
in Socs6 KO or SOCS6 Tg mice [7, 241]. Again, 
redundancy between SOCS family members 
may play a role in the absence of a phenotype 
in these mice. 
Altered SOCS6 expression has been described 
in several disease states, including cancer. 
However, similar to other SOCS proteins, SOCS6 
does not appear to function exclusively as a 
tumor suppressor. Thus, low SOCS6 expression 
has been associated with recurrent primary 
lung squamous cell carcinoma [248] and can-
cers of the liver and thyroid gland [239]. Loss of 
SOCS6 was also observed in over 50% of 
patients with gastric or colorectal cancer, with 
SOCS6 inactivation predominantly caused by 
allelic loss or promoter hypermethylation [249, 
250]. However, in the case of colorectal cancer, 
this did not correlate with disease-free survival 
or overall survival [251]. Ectopic SOCS6 expres-
sion supressed gastric cancer cell growth and 
colony formation in vitro [249]. However, a 
recent study found that levels of SOCS6 expres-
sion in colon and rectum tissue samples taken 
from healthy individuals varied widely, and 
demonstrated that SOCS6 expression was 
increased in gastric cancer [239]. 
SOCS7
SOCS7 has been shown to be expressed in 
many murine tissues [7], but the relative levels 
vary between different mouse strains [8]. In the 
C57BL strain, Socs7 expression was highest in 
isolated pancreatic islets, whole brain, and 
skeletal muscle, with lower levels detected in 
the liver, perigonadal fat, skin, whole pancreas, 
testis and spleen [7, 8]. Expression in the 
129S6 strain was similar overall, but with a 
5-fold decrease in whole brain expression, a 
6-fold increase in spleen expression and a 
2,000-fold decrease in expression in isolated 
pancreatic islets, when compared to the C57BL 
strain [8]. Other sites of expression in this 
strain were the testes, kidney and eye [252]. 
SOCS7 has been shown to be induced by the 
such as ERK1/2 and p38 [244]. SOCS6 can 
also bind to FLT3 and negatively regulate its 
signaling, reducing downstream ERK1/2 signal-
ing and concomitant cell proliferation [243].
A potential role for SOCS6 in neural stem cell 
differentiation has also been suggested. 
Expression of SOCS6 was upregulated during 
differentiation of these cells. SOCS6 overex-
pression resulted in enhanced neurite out-
growth cells, while siRNA-mediated knockdown 
of SOCS6 decreased neurite extension [242]. 
Neurite outgrowth was also enhanced by IGF-1, 
which increased SOCS6 levels, but reduced in 
the presence of a JAK/STAT pathway inhibitor 
that could not be rescued by IGF-1 treatment 
[242]. There is also a large body of in vitro data 
supporting a role for SOCS6 in glucose homeo-
stasis. SOCS6 has been shown to inhibit path-
ways downstream of the INS and IGF-1 recep-
tors [240]. This was facilitated by direct binding 
of SOCS6 to the IRS-4 adaptor protein following 
its phosphorylation in response to IGF-1 or 
insulin and more weakly to IRS-2 in response to 
IGF-1, allowing it to indirectly associate with the 
p85 regulatory subunit of PI3K in response to 
IGF-1 or insulin stimulation [7, 241]. It has been 
suggested that the mechanism of regulation in 
this case might be via preventing recruitment 
of other downstream signaling proteins [7]. 
SOCS6 has also been found to interact with 
PIM3, a protein upregulated in β-cells in 
response to glucose stimulation. Pim3 KO mice 
showed greatly reduced levels SOCS6 expres-
sion in their pancreatic islets, while overexpres-
sion of SOCS6 inhibited glucose-induced 
ERK1/2 activation, suggesting a role for SOCS6 
and PIM3 in the negative regulation of ERK1/2 
in response to glucose stimulation [247]. 
Reduced endogenous SOCS6 in retinal pig-
ment epithelia cells was found to coincide with 
inhibition of insulin signaling. It has therefore 
been suggested that SOCS6 expression may 
serve to maintain high basal insulin/AKT signal-
ing in retina and improve glucose metabolism 
[232]. 
Socs6 KO mice displayed an 8-10% reduction 
in body weight compared to WT littermates, 
thought to be due to perturbation of IGF-1R sig-
naling [7]. However, despite the in vitro data, 
Socs6 knockout mice did not display any altera-
tions in glucose metabolism [7]. It has been 
suggested that this may be due to compensa-
tion by other SOCS family members implicated 
SOCS function
16 Am J Clin Exp Immunol 2013;2(1):1-29
inflammatory cytokines IL-13, IL-6 and TNFα, 
with levels of TSLP and a component of its 
receptor also upregulated [254].
There has only been very limited examination of 
the role of SOCS7 in human disease. However, 
a potential tumor-suppressor role has again 
been indicated, with one study demonstrating 
higher SOCS7 expression was significantly 
associated with earlier stages of cancer and 
overall survival [228]. A recent study has also 
found there to be associations between SOCS7 
haplotypes and various metabolic traits, includ-
ing obesity, insulin resistance and lipid metabo-
lism [255].
Conclusions
Research to date has highlighted a number of 
important roles for SOCS proteins in both devel-
opment and disease. Indeed, all have been 
directly or indirectly implicated in immunity 
and/or hematopoiesis. Many have been shown 
to be involved in disease pathogenesis, includ-
ing inflammatory and other immune disorders, 
susceptibility to infectious diseases and can-
cer. This suggests that there is considerable 
potential for the development of therapeutics 
based on augmenting (or antagonizing) SOCS 
function.
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